Abstract
Coronavirus 2019 (COVID-19) has caused significant disruption to the cell and gene therapy (CGT) industry, which has historically faced substantial complexities in supply of materials, and manufacturing and logistics processes. As decision-makers shifted their priorities to COVID-19-related issues, the challenges in market authorisation, and price and reimbursement of CGTs were amplified. Nevertheless, it is encouraging to see that some CGT developers are adapting their efforts toward the development of promising COVID-19-related therapeutics and vaccines. Manufacturing resilience, digitalisation, telemedicine, value-based pricing, and innovative payment mechanisms will be increasingly harnessed to ensure that market access of CGTs is not severely disrupted.
Keywords: COVID-19; Cell and gene therapies; Health technology assessment; Regulatory.
【저자키워드】 COVID-19, Cell and gene therapies, Health technology assessment, Regulatory., 【초록키워드】 Resilience, Vaccines, Telemedicine, Gene therapy, Regulatory, mechanism, effort, supply, Technology assessment, Cell, authorisation, amplified, caused, increasingly, 【제목키워드】 Cell,